{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:40:26Z","timestamp":1707525626175},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00120-024-02273-y","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T19:02:06Z","timestamp":1705518126000},"page":"171-175","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prim\u00e4re Thromboseprophylaxe zur Vermeidung von ven\u00f6sen Thromboembolien bei ambulanten Tumorpatienten unter Chemotherapie","Primary thromboembolism prophylaxis in outpatient cancer patients receiving chemotherapy"],"prefix":"10.1007","volume":"63","author":[{"given":"D\u00e9sir\u00e9e L.","family":"Dr\u00e4ger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"2273_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008500.pub5","author":"AWS Rutjes","year":"2020","unstructured":"Rutjes\u00a0AWS, Porreca\u00a0E, Candeloro\u00a0M, Valeriani\u00a0E, Di Nisio\u00a0M (2020) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD008500.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"2273_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00761-022-01132-9","volume":"28","author":"M Voigtl\u00e4nder","year":"2022","unstructured":"Voigtl\u00e4nder\u00a0M, Langer\u00a0F (2022) Gerinnungsst\u00f6rungen bei Tumorerkrankungen. Onkologe 28:438\u2013448","journal-title":"Onkologe"},{"issue":"10","key":"2273_CR3","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana\u00a0AA et\u00a0al (2008) Development and validation of a\u00a0predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"8","key":"2273_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carriere","year":"2019","unstructured":"Carriere\u00a0M et\u00a0al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N\u00a0Engl Med 380(8):711\u2013719","journal-title":"N Engl Med"},{"issue":"8","key":"2273_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"A Khorana","year":"2029","unstructured":"Khorana\u00a0A et\u00a0al (2029) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720\u2013728","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"2273_CR6","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"Farge","year":"2019","unstructured":"Farge et\u00a0al (2019) 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566\u2013e581","journal-title":"Lancet Oncol"},{"issue":"5","key":"2273_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key\u00a0NS et\u00a0al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical guideline update. J\u00a0Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"4","key":"2273_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"Lyman","year":"2021","unstructured":"Lyman et\u00a0al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974","journal-title":"Blood Adv"},{"key":"2273_CR9","unstructured":"Riess H et\u00a0al (2020) Thromboembolien bei Tumorpatienten. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/thromboembolien-bei-tumorpatienten-frueher-venoese-thromboembolien-vte-bei-tumorpatienten\/@@guideline\/html\/index\/html. Zugegriffen: 7. Dez. 2023"},{"key":"2273_CR10","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp\u00a0JF et\u00a0al (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122:1712\u20131723","journal-title":"Blood"},{"issue":"2","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"A Lee","year":"2003","unstructured":"Lee\u00a0A et\u00a0al (2003) Low-molecular-weight heparin versus a\u00a0coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N\u00a0Engl J Med 349(2):146\u2013153","journal-title":"N Engl J Med"},{"key":"2273_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","volume":"185","author":"FI Mulder","year":"2020","unstructured":"Mulder\u00a0FI et\u00a0al (2020) Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thromb Res 185:13\u201319","journal-title":"Thromb Res"},{"key":"2273_CR13","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Fonseca P et\u00a0al (2022) Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels. Eur J Intern Med","DOI":"10.1016\/j.ejim.2022.02.020"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02273-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02273-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02273-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T11:02:46Z","timestamp":1707476566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02273-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02273-y","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"4 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.L.\u00a0Dr\u00e4ger gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}